Natrecor for Pulmonary Hypertension in Lung Transplants
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
This study seeks to demonstrate that Natrecor® (nesiritide) is safe and effective and has a
favorable hemodynamic profile in lung transplant recipients that will allow for the avoidance
of inhaled nitric oxide (iNO) use. It is estimated that the use of nesiritide will decrease
the otherwise historically mandated use of iNO by 50%, as compared to the necessity of iNO
use by matched historical controls.